Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

A team of researchers from Case Western Reserve School of Medicine has discovered how the cancer-related protein Bcl-2 signals cancer cells to live longer.

14 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

11 Feb 2014

Study points to molecular pathway to treat recurring, deadly malignancies

Analyzing the genomes of twin 3-year-old sisters – one healthy and one with aggressive leukemia – led an international team of researchers to identify a novel molecular target that could become a way to treat recurring and deadly malignancies.

9 Feb 2014

New study provides important understanding of what drives appetite

While the function of eating is to nourish the body, this is not what actually compels us to seek out food. Instead, it is hunger, with its stomach-growling sensations and gnawing pangs that propels us to the refrigerator - or the deli or the vending machine. Although hunger is essential for survival, abnormal hunger can lead to obesity and eating disorders, widespread problems now reaching near-epidemic proportions around the world.

9 Feb 2014

Findings explain molecular mechanisms underlying microvascular disease in diabetes patients

Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail to heal properly, which can lead to ulcers, chronic infections, and in the most serious cases, limb amputations.

5 Feb 2014

Healthcare experts propose concrete steps for managing shortages of life-saving drugs

A group of prominent healthcare experts including bioethicists, pharmacists, policymakers and cancer specialists have proposed concrete steps for preventing and managing a nightmare scenario that is becoming all too common: shortages of life-saving drugs.

4 Feb 2014

Children who received radiation as part of treatment may have lower long-term survival rates, says study

The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.

4 Feb 2014

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.

30 Jan 2014

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

29 Jan 2014

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia.

29 Jan 2014

BIDMC aims to improve family engagement and reduce overall risk of harm in ICU

Beth Israel Deaconess Medical Center is embarking on a new phase of its mission to eliminate preventable harm, using information technology and system science together with patient and family engagement to head off harm before it happens.

25 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

Miltenyi Biotec announced today that the U.S. Food and Drug Administration has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from a matched related donor.

24 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

Many internists feel ill-equipped to care for childhood cancer survivors

A recent study shows that many internists feel ill-equipped to care for adult patients who are childhood cancer survivors. Eugene Suh, MD, assistant professor in the division of Pediatric Hematology and Oncology at Loyola University Chicago Stritch School of Medicine, was the first author on the study that was conducted at the University of Chicago with Tara Henderson, MD, MPH.

23 Jan 2014

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

23 Jan 2014

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

22 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

Hematology News and Research

Further Reading

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Study points to molecular pathway to treat recurring, deadly malignancies

New study provides important understanding of what drives appetite

Findings explain molecular mechanisms underlying microvascular disease in diabetes patients

Healthcare experts propose concrete steps for managing shortages of life-saving drugs

Children who received radiation as part of treatment may have lower long-term survival rates, says study

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

BIDMC aims to improve family engagement and reduce overall risk of harm in ICU

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Many internists feel ill-equipped to care for childhood cancer survivors

New drug helps children and young adults who have severe pain from sickle cell disease

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo